Impact of renin-angiotensin system targeted therapy on aortic elastic properties assessed by computed tomography

Niya Mileva1,2, Panayot Panayotov1,3, Irina Hristova4

  • 1Medica Cor Hospital, 1713 Ruse, Bulgaria.

Abstract

Insights

Renin-angiotensin system (RAS) targeted therapy improves aortic elastic properties, including compliance and distensibility, in hypertensive patients. This suggests RAS blockade enhances aortic health and reduces cardiovascular risk.

Area of Science:

  • Cardiovascular medicine
  • Radiology
  • Pharmacology

Background:

  • Aortic stiffening is a significant cardiovascular risk factor.
  • Computed tomography (CT) is a key tool for assessing aortic elastic properties.
  • Renin-angiotensin system (RAS) inhibitors are crucial in cardioprotective therapy.

Purpose of the Study:

  • To investigate the relationship between aortic elastic properties and RAS-targeted therapy in hypertensive individuals.
  • To compare aortic compliance and distensibility in patients receiving RAS-targeted therapy versus those not.

Main Methods:

  • An observational prospective study involving hypertensive patients with coronary artery disease undergoing coronary CT angiography (CCTA).
  • Calculation of aortic compliance and distensibility from ECG-gated CCTA images.
  • Stratification of patients into RAS-targeted (RAS+) and non-RAS-targeted (RAS-) therapy groups.

Main Results:

  • Patients on RAS-targeted therapy (RAS+) exhibited significantly higher ascending and descending aorta compliance and distensibility compared to the RAS- group.
  • Excellent correlations were observed between RAS therapy and ascending aorta compliance (r=0.901) and distensibility (r=0.875).
  • Specific values for compliance and distensibility were significantly improved in the RAS+ group (p<0.05 for all).

Conclusions:

  • RAS-blocking treatment is associated with enhanced aortic elastic properties, specifically higher compliance and distensibility.
  • Aortic elastic properties are significantly correlated with RAS-targeted therapy.
  • These findings highlight the beneficial effects of RAS inhibition on aortic health in hypertensive patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
581
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
477
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135